146 related articles for article (PubMed ID: 29165819)
1. Metastasectomy following incomplete response to high-dose interleukin-2.
Hughes T; Broucek J; Iodice G; Bommareddy PK; Basu S; Kaufman HL
J Surg Oncol; 2018 Mar; 117(4):572-578. PubMed ID: 29165819
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
3. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
4. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP
Cancer Immunol Immunother; 2016 Dec; 65(12):1533-1544. PubMed ID: 27714434
[TBL] [Abstract][Full Text] [Related]
5. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Zaid HB; Parker WP; Safdar NS; Gershman B; Erwin PJ; Murad MH; Boorjian SA; Costello BA; Thompson RH; Leibovich BC
J Urol; 2017 Jan; 197(1):44-49. PubMed ID: 27473875
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
8. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
9. [The significance of metastasectomy in patients with metastatic renal cell carcinoma].
Miyata H; Shinohara N; Murahashi N; Tsuchiya K; Miyajima N; Maruyama S; Abe T; Kaga K; Hirano S; Nonomura K
Hinyokika Kiyo; 2015 Feb; 61(2):49-54. PubMed ID: 25812593
[TBL] [Abstract][Full Text] [Related]
10. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.
Yu X; Wang B; Li X; Lin G; Zhang C; Yang Y; Fang D; Song Y; He Z; Zhou L
Biomed Res Int; 2015; 2015():176373. PubMed ID: 26568955
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM
Clark JI; Wong MKK; Kaufman HL; Daniels GA; Morse MA; McDermott DF; Agarwala SS; Lewis LD; Stewart JH; Vaishampayan U; Curti B; Gonzalez R; Lutzky J; Rudraptna V; Cranmer LD; Jeter JM; Hauke RJ; Miletello G; Milhem MM; Amin A; Richart JM; Fishman M; Hallmeyer S; Patel SP; Van Veldhuizen P; Agarwal N; Taback B; Treisman JS; Ernstoff MS; Perritt JC; Hua H; Rao TB; Dutcher JP; Aung S
Clin Genitourin Cancer; 2017 Feb; 15(1):31-41.e4. PubMed ID: 27916626
[TBL] [Abstract][Full Text] [Related]
12. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
17. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
18. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
Spanknebel K; Cheung KY; Stoutenburg J; Hurst-Wicker K; Hesdorffer C; Deraffele G; Kaufman HL
Ann Surg Oncol; 2005 May; 12(5):381-90. PubMed ID: 15915372
[TBL] [Abstract][Full Text] [Related]
19. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
20. Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: an 11-year single-center experience.
Kudelin N; Bölükbas S; Eberlein M; Schirren J
Ann Thorac Surg; 2013 Jul; 96(1):265-70: discussion 270-1. PubMed ID: 23731615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]